Navigation For Mobile

Neuland & Generic Drug Substances (GDS)

From the day Neuland was established in 1984, our core business and operational expertise has been the manufacturing of Generic Drug Substances.

More specifically, delivering niche, highly-specialized and complex synthetic chemistry services. This has long been our strong suit – earning us the identity of a preferred and reliable source across the pharmaceutical industry.

Our knowledge of synthetic chemistry, process development, controlled supply chain and project management, continue to make Neuland an ideal API partner. Our objectives – and our strengths – as a service provider & partner to the pharmaceutical industry are:

  • Consistency in product quality
  • Knowledge and expertise with niche chemistry
  • On-time delivery performance.

Generic Drugs: Being First-to-Market
The Generic Drug Substance (GDS) space has always been highly-competitive. Our clients’ success is often measured in time. The generic that achieves first-to-market will secure significant market advantages. Project & process efficiency are mission-critical.

With new FDA guidelines recently announced to speed up generic pathways to market, it looks as though annual generic drug market growth of 10.8% remains on track.

From a Zion Market Research report (May, 2017):

“…the global generic drug market accounted for around USD 200.20 billion in 2015 and is expected to reach approximately USD 380.60 billion by 2021, growing at a CAGR of around 10.8 % between 2016 and 2021.”

A 2017 BCC Research report found:

The global market for generic drugs should reach $533 billion by 2021 from $352 billion in 2016 at a compound annual growth rate (CAGR) of 8.7%, from 2016 to 2021.

The fact that the generics market is growing is perhaps less newsworthy – at least for us inside the industry – than the ways in which drug development and manufacturing are evolving. From virtual crowd-sourced clinical trials to the advent of QbD & DoE to our ever-expanding discoveries and capabilities in the field of chemistry, drug research & commercialization is in a near-constant state of improvement and change.

Today’s generics space is exciting. New technologies and methodologies are evolving the drug industry, creating new opportunities for API domain expertise and excellence.

Want to learn more about Neuland’s Generic Drug Substances capabilities? Download Neuland’s Generic Drug Substances Brochure (PDF, late 2017).

Comments are closed.